NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Recruiting
PHASE1Ages 18+InterventionalTreatmentBeOne Medicines
~258 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:SonrotoclaxZanubrutinib
At a glance
Recruiting sites
6 of 17 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants who Experience Tumor Lysis Syndrome (TLS)
Measured over Up to approximately 4 months
Conditions
Where it's being run
17 sites across 12 statesFrance3
Victoria2
Western Australia2
United Kingdom2
Florida1
Indiana1
Kansas1
Massachusetts1
Study leadership
- Study Director · STUDY_DIRECTOR · BeOne Medicines
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants who Experience Tumor Lysis Syndrome (TLS)Up to approximately 4 months
TLS will be defined by Howard criteria during the schedule-limiting toxicity (SLT) evaluation window